Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago? We need to look for a comparison against the company's own recent past, already real and recurring, and early stage. In the transcript, management discusses growth in loans and deposits, but that's overall growth. They mention market disruption from KeyBank/First Niagara, and they are capturing customers. They talk about organic growth. They mention that only 30% of growth is from disruption, rest organic. They talk about commercial loan growth, C&I growth, etc. But do they specifically say that the size of individual deals, loans, or customers is increasing? They mention that they are getting new customers, but not that each new customer is larger than before. They mention that they have a government banking department and hired a director, but that's new business line. They mention insurance agency acquisitions, but that's not about size of deals. They talk about loan growth across all categories, but that could be volume. They don't say "the average loan size has increased" or "we are now landing larger projects than before." They mention that they are taking advantage of market disruption, but that's about capturing more customers, not necessarily larger ones. They also mention that they expect double-digit growth in loans for 2017, but that's growth rate, not unit size. There is no explicit statement about the size of individual engagements increasing. They talk about expanding commercial loan portfolio, but not that each loan is bigger. They mention that they are diversifying into C&I, but that's a different product. The question is specific: "successive engagements of the same kind are coming in at progressively larger size." That would be like, "we used to do $1 million loans, now we are doing $5 million loans." No such statement. They mention that they have a pipeline, but that's not about size. They also mention that they are putting capital to work, but that's not about deal size. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.